Xiuning Le, M.D., Ph.D.
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2010 | Harvard Medical School, Boston, MA, USA, PHD, Biological and Biomedical Sciences |
| 2003 | Peking Union Medical College, Beijing, CHN, MD, Clinical Medicine |
Postgraduate Training
| 2014-2017 | Research Fellowship, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA |
| 2013-2016 | Clinical Fellowship, Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA |
| 2010-2013 | Clinical Residency, Internal Medicine, University of Massachusetts Medical Center, Worcester, MA |
Board Certifications
| 2016 | American Board Internal Medicine, Medical Oncology |
| 2013 | American Board Internal Medicine, Internal Medicine |
Experience & Service
Academic Appointments
Instructor, Department of Hematology Oncology, Division of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA, 2016 - 2017
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB, Viteri S, Mazieres J, Smit EF, Thomas M, Iams WT, Cho BC, Kim HR, Yang JC, Chen YM, Patel JD, Bestvina CM, Park K, Griesinger F, Johnson M, Gottfried M, Britschgi C, Heymach J, Sikoglu E, Berghoff K, Schumacher KM, Bruns R, Otto G, Paik PK. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res 28(6):1117-1126, 2022. e-Pub 2021. PMID: 34789481.
- F Smit E, Dooms C, Raskin J, Nadal E, Tho LM, Le X, Mazieres J, S Hin H, Morise M, W Zhu V, Tan D, H Holmberg K, Ellers-Lenz B, Adrian S, Brutlach S, Schumacher KM, Karachaliou N, Wu YL. INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. Future Oncol 18(9):1039-1054, 2022. e-Pub 2021. PMID: 34918545.
- Patel SA, Herynk MH, Cascone T, Saigal B, Nilsson MB, Tran H, Ramachandran S, Diao L, Wang J,Le X,, Minna J, Wistuba II, Heymach JV. Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. J Thorac Oncol 16(12):2051-2064, 2021. e-Pub 2021. PMID: 34311109.
- Yu HA, Goldberg SB, Le, X , Piotrowska Z, Goldman JW, De Langen AJ, Okamoto I, Cho BC, Smith P, Mensi I, Ambrose H, Kraljevic S, Maidment J, Chmielecki J, Li-Sucholeiki X, Doughton G, Patel G, Jewsbury P, Szekeres P, Riess JW. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clin Lung Cancer 22(6):601-606, 2021. e-Pub 2021. PMID: 34389237.
- Lewis WE, Hong L, Mott FE, Simon G, Wu CC, Rinsurongkawong W, Lee JJ, Lam VK, Heymach JV, Zhang J, Le, X . Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clin Res Rep 2(11):100237, 2021. e-Pub 2021. PMID: 34820641.
- Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, Chen Y, Wu M, Behrens C, Chow CW, Pham HHN, Fukuoka J, Wu J, Parra ER, Little LD, Gumbs C, Song X, Wu CJ, Diao L, Wang Q, Cardnell R, Zhang J, Wang J, Le, X , Gibbons DL, Heymach JV, Jack Lee J, William WN, Cheng C, Glisson B, Wistuba I, Andrew Futreal P, Thomas RK, Reuben A, Byers LA, Zhang J. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun 12(1):6655, 2021. e-Pub 2021. PMID: 34789716.
- Tian P, Zeng H, Ji L, Ding Z, Ren L, Gao W, Fan Z, Li L, Le X, Li P, Zhang M, Xia X, Zhang J, Li Y, Li W. Lung adenocarcinoma with ERBB2 exon 20 insertions: comutations and immunogenomic features related to chemoimmunotherapy. Lung Cancer 160:50-58, 2021. e-Pub 2021. PMID: 34403912.
- Robichaux JP, Le, X , Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JV. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597(7878):732-737, 2021. e-Pub 2021. PMID: 34526717.
- Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 70(7):1965-1976, 2021. e-Pub 2021. PMID: 33416944.
- Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le, X , Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross ND. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck 43(5):1592-1603, 2021. e-Pub 2021. PMID: 33522021.
- Le, X , Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol 16(4):583-600, 2021. e-Pub 2020. PMID: 33388477.
- Nilsson MB, Robichaux J, Herynk MH, Cascone T, Le, X , Elamin Y, Patel S, Zhang F, Xu L, Hu L, Diao L, Shen L, He J, Yu X, Nikolinakos P, Saintigny P, Fang B, Girard L, Wang J, Minna JD, Wistuba II, Heymach JV. Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. J Thorac Oncol 16(3):439-451, 2021. e-Pub 2020. PMID: 33309987.
- Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le, X , Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
- Le, X , Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, Ares LP, Frimodt-Moller B, Wolff K, Visseren-Grul C, Heymach JV, Garon EB. Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol 16(2):205-215, 2021. e-Pub 2020. PMID: 33096270.
- Hong L, Zhang J, Heymach JV, Le, X . Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer. Ther Adv Med Oncol 13:1758835921992976, 2021. e-Pub 2021. PMID: 33643443.
- Yu H, Goldberg GB, Le, X , Piotrowska Z, Goldman JW, Langen JD, Okamoto I, Cho BC, Smith P, Mensi I, Kirova BK, Chmielecki J, Li-Sucholeicki X, Doughton G, Patel G, Jewsbury P, Szekeres P, Riess JW. Biomarker-directed Phase II Platform Study in Patients with EGFR Sensitizing Mutation-positive Advanced/Metastatic Non-small Cell Lung Cancer Whose Disease has Progressed on First-line Osimertinib Therapy. Clinical Lung Cancer, 2021.
- Le X,, Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D, Tsao A, Hong D, Raymond V, Paik P, Zhang J, Heymach JV. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34957368.
- Liu X, Hong L, Nilsson M, Hubert SM, Wu S, Rinsurongkawong W, Lewis J, Spelman A, Roth J, Swisher S, He Y, Jack Lee J, Fang B, Heymach JV, Zhang J, Le, X . Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer 149:33-40, 2020. e-Pub 2020. PMID: 32956986.
- Jin Y, Bao H, Le, X , Fan X, Tang M, Shi X, Zhao J, Yan J, Xu Y, Quek K, Elamin YY, Zhang J, Futreal PA, Wistuba II, Heymach JV, Lou G, Shao L, He Q, Lin C, Wu X, Shao YW, Wang X, He J, Chen Y, Stebbing J, Chen M, Zhang J, Yu X. Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene 39(9):1846-1859, 2020. e-Pub 2019. PMID: 31754213.
- Le, X , Cornelissen R, Garassino M, Clarke JM, Tchekmedyian N, Goldman JW, Leu SY, Bhat G, Lebel F, Heymach JV, Socinski MA. Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol:JCO2101323. e-Pub 2021. PMID: 34843401.
- Robichaux JP, Le X , Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete L, Rinsurongkawong W, Zhang S, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha M, Cross JB, Gray JE and Heymach JV. Structure-based classification predicts drug response in EGFR mutant lung cancer. Nature.
- Patel SA, Herynk MH, Cascone T, Saigal B, Nilsson MB, Tran H, Ramachandran S, Diao L, Wang, Le X , J, Minna J, Wistuba II, Heymach JV.. Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer. Journal of Thoracic Oncology.
Grant & Contract Support
| Title: | Conquer Cancer Foundation ASCO Young Investigator Award |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | dissecting mechanisms of resistance to high-order therapeutic combinations in breast cancer |
| Funding Source: | SU2C-TVF Convergence Program |
| Role: | Principal Investigator |
| Title: | understanding PIM1 upregulation as a novel mechanism of resistance to PI3K inhibition in breast cancer |
| Funding Source: | Claudia Adams Barr Program for Innovative Cancer Research |
| Role: | Principal Investigator |
| Title: | Paul Calabresi Clinical Oncology Award |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | |
| Funding Source: | Discovery Grant-Innovation in Cancer Informatics |
| Role: | Co-Principal Investigator |
| Title: | Project 2: Novel therapeutic strategies to enhance antitumor immunity immunologically inert subgroups of non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Feasibility analysis of single-cell RNAseq in HPV positive Head and Neck Squamous Cell |
| Funding Source: | MDACC - Steifel Clinical Trails |
| Role: | Co-Principal Investigator |
| Title: | Understanding the impact of anti-VEGF therapy on resistance mechanisms and immune modulation in EGFR-mutant NSCLC |
| Funding Source: | ASCO Conquer Cancer Foundation |
| Role: | Principal Investigator |
| Title: | A phase 2 study to assess the effect of anti-PD1 therapy on viral clearance in HPV-associated oropharyngeal cancer patients with persistent HPV detection in the oral rinse and/or plasma cfDNA after definitive therapy |
| Funding Source: | MDACC Oropharynx Program Stiefel/Clinical Trails |
| Role: | Principal Investigator |
| Title: | Overcoming resistance to dual VEGF/EGFR inhibition in EGFR-mutant NSCLC |
| Funding Source: | Khalifa Scholar Award |
| Role: | Principal Investigator |
| Title: | Development of Novel immunothrapy for EGFR-mutant NSCLC |
| Funding Source: | Rexanna's Foundation |
| Role: | Principal Investigator |
| Title: | Development of Novel Therapeutic Strategies for MET-altered NSCLC |
| Funding Source: | MET Crusadors Foundation |
| Role: | Principal Investigator |
| Title: | Functional Characterization of Peripheral T Cells Reactivity to Common Neoangtigens in HPV positive Head and Neck Squamous Cell |
| Funding Source: | MDACC - Steifel Clinical Trails |
| Role: | Principal Investigator |